Testing effectiveness (Phase 2)Looking for participantsNCT03694236
What this trial is testing
Concurrent Neoadjuvant Chemoradiotherapy Plus Durvalumab (MEDI4736) in Resectable Stage III NSCLC
Who this might be right for
Potentially Resectable Stage II/IIIa NSCLC
Yonsei University 39